'Clean athlete status' cannot be certified: Calling for caution, evidence and transparency in 'alternative' anti-doping systems.

Anti-doping Athlete Athlete Biological Passport Athlete entourage Athlete support personnel Clean sport Doping attitude Testing Therapeutic Use Exemption Whereabouts

Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
07 2021
Historique:
received: 03 07 2020
revised: 17 10 2020
accepted: 30 10 2020
pubmed: 1 12 2020
medline: 11 8 2021
entrez: 30 11 2020
Statut: ppublish

Résumé

Athletes, sponsors and sport organisations all have a vested interest in upholding the values of clean sport. Despite the considerable and concerted efforts of the global anti-doping system over two decades, the present system is imperfect. Capitalising upon consequent frustrations of athletes, event organisers and sponsors, alternative anti-doping systems have emerged outside the global regulatory framework. The operating principles of these systems raise several concerns, notably including accountability, legitimacy and fairness to athletes. In this paper, we scrutinise the Clean Protocol™, which is the most comprehensive alternative system, for its shortcomings through detailed analysis of its alleged logical and scientific merits. Specifically, we draw the attention of the anti-doping community - including researchers and practitioners - to the potential pitfalls of using assessment tools beyond the scope for which they have been validated, and implementing new approaches without validation. Further, we argue that whilst protecting clean sport is critically important to all stakeholders, protocols that put athletes in disadvantageous positions and/or pose risks to their professional and personal lives lack legitimacy. We criticise the use of anti-doping data and scientific research out of context, and highlight unintended harms that are likely to arise from the widespread implementation of such protocols in parallel with - or in place of - the existing global anti-doping framework.

Identifiants

pubmed: 33250439
pii: S0955-3959(20)30368-6
doi: 10.1016/j.drugpo.2020.103030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103030

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declarations of Interest The authors declare no conflict of interest. All authors are active researchers and practitioners in anti-doping, many serving in unpaid advisory positions with anti-doping organisations and have benefitted from competitively awarded research funding for anti-doping research. None of these activities are related to the content of this paper.

Auteurs

Andrea Petróczi (A)

School of Life Sciences, Pharmacy and Chemistry, Faculty of Science, Engineering and Computing, Kingston University London, Penrhyn Road, Kingston-upon-Thames, Surrey, KT1 2EE, United Kingdom. Electronic address: a.petroczi@kingston.ac.uk.

Susan H Backhouse (SH)

Carnegie School of Sport, Leeds Beckett University, Leeds, United Kingdom.

Ian D Boardley (ID)

School of Sport, Exercise, and Rehabilitation Sciences, University of Birmingham, United Kingdom.

Martial Saugy (M)

Institute of Sports Science, University of Lausanne, Switzerland.

Yannis Pitsiladis (Y)

Collaborating Centre of Sports Medicine, University of Brighton, Eastbourne, United Kingdom.

Marjolaine Viret (M)

Institute of Sports Science, University of Lausanne, Switzerland.

Gregory Ioannidis (G)

Department of Law & Criminology, Sheffield Hallam University, United Kingdom.

Fabien Ohl (F)

Institute of Sports Science, University of Lausanne, Switzerland.

Sigmund Loland (S)

Department of Sport and Social Sciences, Norwegian School of Sport Sciences, Norway.

Mike McNamee (M)

Department of Movement Sciences, KU Leuven, Belgium; School of Sport and Exercise Sciences, Swansea University, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH